Olgu Sunumu 7 Yaşındaki Bir Erkek Çocukta Atomoksetin ile İndüklenen Raynaud Fenomeni

Öz

Atomoksetin, DEHB tedavisinde kullanılan, FDA onaylı non-stimülan farmakolojik ajanlardan biridir. Genellikle hastaların psikostimülanlara yanıt vermediği veya bunları tolere edemediği durumlarda kullanılır. En sık bildirilen yan etkiler arasında iştahsızlık, karın ağrısı, baş ağrısı ve sinirlilik yer almaktadır. Bununla birlikte, literatürde nadiren bildirilen yan etkilerden biri de Raynaud fenomenidir. Bu yazıda, atomoksetin uygulamasından sonra Raynaud fenomeni gelişen 7 yaşında bir erkek hasta sunulmuştur.

Anahtar Kelimeler

• Atomoksetin
• Çocuk
• DEHB
• Reynaud fenomeni

Destekleyen Kurum

Yok.

Etik Beyan

Bu bir vaka sunumu olduğundan, hastanın ailesinden aydınlatılmış onam alınmıştır; etik kurul belgesi bulunmamaktadır.

Atomoxetine Induced Raynaud's Phenomenon in a 7-Year-Old Male: A Case Report

Öz

Atomoxetine is one of the FDA-approved non-stimulant pharmacological agents used in the treatment of ADHD. It is commonly used in cases where patients are unresponsive to or unable to tolerate psychostimulants. The most frequently reported side effects include loss of appetite, abdominal pain, headache, and irritability. However, one of the rarely reported side effects in the literature is Raynaud’s phenomenon. In this case, we present a 7-year-old male who developed Raynaud’s phenomenon following the administration of atomoxetine.

Anahtar Kelimeler

• ADHD
• Atomoxetine
• Child
• Raynaud’s phenomenon

Destekleyen Kurum

None

Etik Beyan

This is a case report, and informed consent was obtained from the patient's family; there is no ethics committee approval.

Kaynakça

1. Bertoli, R., Girardin, F., Russmann, S., & Lauterburg, B. H. (2003). Raynaud’s phenomenon induced by drugs acting on neurotransmission: Two cases under reboxetine and one under tegaserod. European Journal of Clinical Pharmacology, 58(10), 717–721. https://doi.org/10.1007/s00228-002-0552-4
2. Besag, F. M. C., Vasey, M. J., Roy, S., & Cortese, S. (2025). Raynaud syndrome associated with medication for attention-deficit/hyperactivity disorder: A systematic review. CNS Drugs, 39(3), 213–241. https://doi.org/10.1007/s40263-024-01154-4
3. Cooke, J. P., & Marshall, J. M. (2005). Mechanisms of Raynaud’s disease. Vascular Medicine, 10(4), 293–307. https://doi.org/10.1191/1358863x05vm639ra
4. Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., Doepfner, M., Dittmann, R. W., Ferrin, M., Holtmann, M., Santosh, P., Sergeant, J., Simonoff, E., Zuddas, A., Taylor, E., … Cipriani, A. (2018). Comparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738. https://doi.org/10.1016/S2215-0366(18)30269-4
5. Gökçen, C., Kütük, M. O., & Coşkun, Ş. (2013). Dose-dependent Raynaud’s phenomenon developing from use of atomoxetine in a girl. Journal of Child and Adolescent Psychopharmacology, 23(6), 428–430. https://doi.org/10.1089/cap.2012.0131
6. Gülle, Z. N., Karayagmurlu, A., & Coşkun, M. (2019). Raynaud’s phenomenon related with atomoxetine treatment in a child with autism and attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 29(8), 649–650. https://doi.org/10.1089/cap.2019.0025
7. Khouri, C., Blaise, S., Carpentier, P., Villier, C., Cracowski, J.-L., & Roustit, M. (2016). Drug-induced Raynaud’s phenomenon: Beyond β-adrenoceptor blockers. British Journal of Clinical Pharmacology, 82(1), 6–16. https://doi.org/10.1111/bcp.12902
8. Pope, J. (2013). Raynaud’s phenomenon (primary). BMJ Clinical Evidence, 2013, Article 1119.

9. Sama, C. B. (2016). Post-traumatic digital gangrene associated with epinephrine use in primary Raynaud’s phenomenon: Lesson for the future. Ethiopian Journal of Health Sciences, 26(4), 401–404. https://doi.org/10.4314/ejhs.v26i4.13
10. U.S. Food and Drug Administration. (2023). FDA-approved medications for attention-deficit/hyperactivity disorder.